SP . Price movement, page-33

15 cents will play a crucial role as support.
If that holds, we will be off higher on a sustainable basis, provided those clinical trial results are good enough to bring in orders.
VTM interference, as mentioned, is my main concerns. Market will not differentiate between stored and live samples, and it would be an uphill battle to verify results later.
Hence the Indian patient trials to be pulled forward 6 months, wise decision by management.
That should allow to share some early indicators from those trials during initial product
rollout.

Should we break 15 cents, I will be accumulating.
As for now, this is a hold, as we are very highly valued and several contracts are built into
price.
The Ellume raw material income will be gradual and moderate.
This to me translates as confirmation to about 4 to 5 mil in receipts for the calendar year.
Current share price also incorporates about 8 mil tests done in Operon yearly.
Anything less of capacity would see us struggling to hold onto MC.
Anything way above will see us readjusting higher.

This is now a numbers game, less so a speculative game and share price will look for
such indicators once this rally dies out.


all IMO